Trials / Unknown
UnknownNCT01781754
Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients
Changes in UCP2 mRNA in T2DM Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Tel-Aviv Sourasky Medical Center · Other Government
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress. The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood withdrawal | This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin). |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-02-01
- Last updated
- 2013-02-01
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01781754. Inclusion in this directory is not an endorsement.